| __timestamp | Ionis Pharmaceuticals, Inc. | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 241751000 | 22746000000 |
| Thursday, January 1, 2015 | 322292000 | 21536000000 |
| Friday, January 1, 2016 | 344320000 | 21685000000 |
| Sunday, January 1, 2017 | 374644000 | 25354000000 |
| Monday, January 1, 2018 | 1820000 | 27091000000 |
| Tuesday, January 1, 2019 | 4000000 | 27556000000 |
| Wednesday, January 1, 2020 | 12000000 | 28427000000 |
| Friday, January 1, 2021 | 11000000 | 23402000000 |
| Saturday, January 1, 2022 | 14000000 | 24596000000 |
| Sunday, January 1, 2023 | 9133000 | 26553000000 |
| Monday, January 1, 2024 | 11215000 | 27471000000 |
Unleashing the power of data
In the ever-evolving landscape of pharmaceuticals, understanding cost structures is crucial. Johnson & Johnson, a titan in the industry, consistently reported a cost of revenue exceeding $20 billion annually from 2014 to 2023. This reflects their expansive operations and market dominance. In contrast, Ionis Pharmaceuticals, Inc., a smaller player, showed a more volatile cost pattern, peaking in 2017 with a cost of revenue around $375 million, before stabilizing to approximately $9 million by 2023.
While Johnson & Johnson's cost of revenue grew by about 17% over the decade, Ionis experienced a dramatic 97% decrease from its 2017 peak. This divergence highlights the differing scales and strategies of these companies. For investors and industry analysts, these trends offer a window into operational efficiencies and market positioning, underscoring the importance of scale in the pharmaceutical sector.
Cost of Revenue Comparison: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Cost Insights: Breaking Down Johnson & Johnson and Cytokinetics, Incorporated's Expenses
Johnson & Johnson vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Sanofi and Ionis Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Ionis Pharmaceuticals, Inc.
Cost of Revenue Trends: Pharming Group N.V. vs Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Ionis Pharmaceuticals, Inc. vs Alkermes plc
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.